These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19122313)

  • 21. The discovery of diazepinone-based 5-HT3 receptor partial agonists.
    Manning DD; Guo C; Zhang Z; Ryan KN; Naginskaya J; Choo SH; Masih L; Earley WG; Wierschke JD; Newman AS; Brady CA; Barnes NM; Guzzo PR
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2578-81. PubMed ID: 24755431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
    Lembo A; Weber HC; Farraye FA
    Drugs; 2003; 63(18):1895-905. PubMed ID: 12930162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Design, synthesis and bioactivity of aryl piperazine benzo[b][1,4]oxazine derivatives].
    Zheng YY; Xie P; Zhang J; Li JQ; Guo L; Yu LP; Zhou B
    Yao Xue Xue Bao; 2012 Jun; 47(6):755-63. PubMed ID: 22919723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, synthesis and evaluation of antidepressant activity of novel 2-methoxy 1, 8 naphthyridine 3-carboxamides as 5-HT3 receptor antagonists.
    Mahesh R; Dhar AK; Jindal A; Bhatt S
    Chem Biol Drug Des; 2014 May; 83(5):583-91. PubMed ID: 24330585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benzimidazole derivatives. Part 5: design and synthesis of new benzimidazole-arylpiperazine derivatives acting as mixed 5-HT1A/5-HT3 ligands.
    López-Rodríguez ML; Benhamú B; Morcillo MJ; Tejada I; Avila D; Marco I; Schiapparelli L; Frechilla D; Del Río J
    Bioorg Med Chem; 2004 Oct; 12(19):5181-91. PubMed ID: 15351401
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug development: A healthy pipeline.
    Morgan B
    Nature; 2016 May; 533(7603):S116-7. PubMed ID: 27191492
    [No Abstract]   [Full Text] [Related]  

  • 28. Microwave assisted synthesis of 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists.
    Mahesh R; Perumal RV; Pandi PV
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5179-81. PubMed ID: 15380223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome.
    Spiller RC
    Curr Opin Pharmacol; 2011 Feb; 11(1):68-74. PubMed ID: 21398180
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-Based Discovery of Novel and Selective 5-Hydroxytryptamine 2B Receptor Antagonists for the Treatment of Irritable Bowel Syndrome.
    Zhou Y; Ma J; Lin X; Huang XP; Wu K; Huang N
    J Med Chem; 2016 Jan; 59(2):707-20. PubMed ID: 26700945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigations on the 1-(2-biphenyl)piperazine motif: identification of new potent and selective ligands for the serotonin(7) (5-HT(7)) receptor with agonist or antagonist action in vitro or ex vivo.
    Lacivita E; Patarnello D; Stroth N; Caroli A; Niso M; Contino M; De Giorgio P; Di Pilato P; Colabufo NA; Berardi F; Perrone R; Svenningsson P; Hedlund PB; Leopoldo M
    J Med Chem; 2012 Jul; 55(14):6375-80. PubMed ID: 22738316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy of arylpiperazine derivatives at the central 5-HT3 receptors.
    Cappelli A; Anzini M; Vomero S; Canullo L; Mennuni L; Makovec F; Doucet E; Hamon M; Menziani MC; De Benedetti PG; Bruni G; Romeo MR; Giorgi G; Donati A
    J Med Chem; 1999 May; 42(9):1556-75. PubMed ID: 10229626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening of 5-HT1A receptor antagonists using molecularly imprinted polymers.
    O'Connor NA; Paisner DA; Huryn D; Shea KJ
    J Am Chem Soc; 2007 Feb; 129(6):1680-9. PubMed ID: 17284006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benzoxazole derivatives as novel 5-HT3 receptor partial agonists in the gut.
    Sato Y; Yamada M; Yoshida S; Soneda T; Ishikawa M; Nizato T; Suzuki K; Konno F
    J Med Chem; 1998 Jul; 41(16):3015-21. PubMed ID: 9685241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
    Komoto S; Miura S
    Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan.
    Childers WE; Abou-Gharbia MA; Kelly MG; Andree TH; Harrison BL; Ho DM; Hornby G; Huryn DM; Potestio L; Rosenzweig-Lipson SJ; Schmid J; Smith DL; Sukoff SJ; Zhang G; Schechter LE
    J Med Chem; 2005 May; 48(10):3467-70. PubMed ID: 15887953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of serotonin in irritable bowel syndrome: implications for management.
    Garvin B; Wiley JW
    Curr Gastroenterol Rep; 2008 Aug; 10(4):363-8. PubMed ID: 18627647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripherally acting therapies for the treatment of irritable bowel syndrome.
    Saad RJ
    Gastroenterol Clin North Am; 2011 Mar; 40(1):163-82. PubMed ID: 21333906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. I. Synthesis and structure-activity relationships of conformationally restricted fused imidazole derivatives.
    Ohta M; Suzuki T; Koide T; Matsuhisa A; Furuya T; Miyata K; Yanagisawa I
    Chem Pharm Bull (Tokyo); 1996 May; 44(5):991-9. PubMed ID: 8689729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.
    Ford AC; Brandt LJ; Young C; Chey WD; Foxx-Orenstein AE; Moayyedi P
    Am J Gastroenterol; 2009 Jul; 104(7):1831-43; quiz 1844. PubMed ID: 19471254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.